Table 1.
Characteristics of the included studies.
| First Author | Year | Region | Subtype | Number | Sex (M/F) | Age (range) | EZH2 mutations |
|---|---|---|---|---|---|---|---|
| Grossmann V | 2011 | Germany | AML | 81 | 57/24 | 72.8 (40–85.5) | 9 (11.1%) |
| Saygin C | 2018 | America | AML | 100 | 52/48 | 58.5 (24–75) | 5 (5.0%) |
| Wang XL | 2013 | China | MDS | 714 | 396/318 | 43 (8–83) | 13 (1.8%) |
| Wang JY | 2013 | China | MDS | 153 | 106/47 | 51 (16–81) | 8 (5.2%) |
| Bejar R | 2012 | America | MDS | 288 | 203/85 | 69 (15–90) | 23 (8.0%) |
| Tobiasson M | 2016 | Sweden and UK | MDS | 134 | Unknown | 70.5 (35–88) | 12 (9.0%) |
| SN Khan | 2013 | America | MDS, MDS/MPN, MPN, AML | 469 | Unknown | Unknown | 38 (8.0%) |
| Wu LY | 2015 | China | MDS | 304 | 162/142 | 57 (11–89) | 11 (3.6%) |